Tiverton Asset Management’s Sage Therapeutics SAGE Stock Holding History

Tiverton Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$1.06M	Hold	7,550	–	–	0.04%	289
2019 Q2	$1.38M	Buy	7,550 +27	+0.4%	+$4.61K	0.05%	233
2019 Q1	$1.2M	Buy	7,523 +1,323	+21%	+$192K	0.05%	220
2018 Q4	$594K	Sell	6,200 -306	-5%	-$35K	0.04%	218
2018 Q3	$919K	Buy	6,506 +5,044	+345%	+$779K	0.05%	205
2018 Q2	$229K	Buy	+1,462	New	+$230K	0.01%	303

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Tiverton Asset Management's SAGE Position: Q3 2019 in Review

Tiverton Asset Management held its Sage Therapeutics (SAGE) position steady in Q3 2019 at 7,550 shares worth $1.06M. The position accounts for 0.04% of the portfolio, ranked #289.

Tiverton Asset Management first reported a position in SAGE in Q2 2018 and has held it in 6 quarters since. The position peaked at $1.38M in Q2 2019. 285 funds tracked by Wall St. Rank hold SAGE as of Q3 2019.

Tiverton Asset Management held 7,550 shares of Sage Therapeutics worth $1.06M as of Q3 2019.
Tiverton Asset Management left its Sage Therapeutics share count unchanged in Q3 2019.
Sage Therapeutics made up 0.04% of Tiverton Asset Management's portfolio in Q3 2019, its #289 holding.
Tiverton Asset Management first reported a position in Sage Therapeutics in Q2 2018 and has held it in 6 quarters since.
Tiverton Asset Management's Sage Therapeutics position peaked at $1.38M in Q2 2019.
285 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.